| Dr John Lee Blankenship, MD | |
|
629 Nuckolls Rd, Bolivar, TN 38008-1599 | |
| (731) 658-3388 | |
| (731) 658-4079 |
| Full Name | Dr John Lee Blankenship |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 629 Nuckolls Rd, Bolivar, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346222593 | NPI | - | NPPES |
| 36219 | Other | TN | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 36219 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Volunteer Homecare Of West Tn | Parsons, TN | Home health agency |
| Medical Center Home Health | Jackson, TN | Home health agency |
| Jackson-madison County General Hospital | Jackson, TN | Hospital |
| Bolivar General Hospital | Bolivar, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hardeman County Community Health Center | 5799694147 | 8 |
News Archive
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
RTI International Metals, Inc.,, released results today for the third quarter of 2010.
The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI).
A study published in The Lancet on 19th January 2017 entitled ‘Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study' shows that using advanced MRI almost doubles the number of aggressive tumours detected.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
› Verified 3 days ago
| Entity Name | Hardeman County Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861468340 PECOS PAC ID: 5799694147 Enrollment ID: O20040615001290 |
News Archive
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
RTI International Metals, Inc.,, released results today for the third quarter of 2010.
The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI).
A study published in The Lancet on 19th January 2017 entitled ‘Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study' shows that using advanced MRI almost doubles the number of aggressive tumours detected.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Lee Blankenship, MD Po Box 720, Bolivar, TN 38008-0720 Ph: (731) 658-3388 | Dr John Lee Blankenship, MD 629 Nuckolls Rd, Bolivar, TN 38008-1599 Ph: (731) 658-3388 |
News Archive
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
RTI International Metals, Inc.,, released results today for the third quarter of 2010.
The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI).
A study published in The Lancet on 19th January 2017 entitled ‘Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study' shows that using advanced MRI almost doubles the number of aggressive tumours detected.
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
› Verified 3 days ago
Dr. Robert Wayne Dunavant, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 Nuckolls Rd, Bolivar, TN 38008 Phone: 731-658-7111 Fax: 731-658-4328 | |
Dr. Samuel Terry Johnson Jr., M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 629 Nuckolls Rd, Bolivar, TN 38008 Phone: 731-658-3388 Fax: 731-658-4079 | |
Lawrence Diaz, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 629 Nuckolls Rd, Bolivar, TN 38008 Phone: 731-658-3388 Fax: 731-658-4079 | |
Olufemi E Soyinka, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 629 Nuckolls Rd, Bolivar, TN 38008 Phone: 731-658-3388 Fax: 731-658-4079 | |
Dr. Nithyananda Pakkala, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 630 Nuckolls Rd, Bolivar, TN 38008 Phone: 731-658-6011 Fax: 731-658-9884 | |
Mrs. Holly Brooke Shourd, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1359 W Market St., Bolivar, TN 38008 Phone: 731-361-1003 |